Literature DB >> 26775904

Health State Utility Impact of Breast Cancer in U.S. Women Aged 18-44 Years.

Derek S Brown1, Justin G Trogdon2, Donatus U Ekwueme3, Linda Chamiec-Case4, Gery P Guy3, Florence K Tangka3, Chunyu Li3, Katrina F Trivers3, Juan L Rodriguez3.   

Abstract

INTRODUCTION: Breast cancer affects women's health-related quality of life negatively, but little is known about how breast cancer affects this in younger women aged 18-44 years. This study measures preference-based health state utility (HSU) values, a scaled index of health-related quality of life for economic evaluation, for younger women with breast cancer and compares these values with same-age women with other cancers and older women (aged ≥45 years) with breast cancer.
METHODS: Data from the 2009 and 2010 Behavioral Risk Factor Surveillance System were analyzed in 2014. The sample included 218,852 women; 7,433 and 18,577 had histories of breast and other cancers. HSU values were estimated using Healthy Days survey questions and a published mapping algorithm. Linear regression models for HSU were estimated by age group (18-44 and ≥45 years).
RESULTS: The adjusted breast cancer HSU impact was four times larger for younger women than for older women (-0.097 vs -0.024, p<0.001). For younger women, the effect of breast cancer on HSU was 70% larger than that of other cancers (-0.097 vs -0.057, p=0.024).
CONCLUSIONS: Younger breast cancer survivors reported lower HSU values than older survivors, highlighting the impact of breast cancer on the physical and mental health of younger women. The estimates may be used to evaluate quality-adjusted life-years or expectancy for prevention or treatment of breast cancer. This study also indicates that separate quality of life adjustments for women by age group are important for economic analysis of public health breast cancer interventions.
Copyright © 2016 American Journal of Preventive Medicine. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26775904     DOI: 10.1016/j.amepre.2015.07.020

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  7 in total

1.  Medical costs of treating breast cancer among younger Medicaid beneficiaries by stage at diagnosis.

Authors:  Justin G Trogdon; Donatus U Ekwueme; Diana Poehler; Cheryll C Thomas; Katherine Reeder-Hayes; Benjamin T Allaire
Journal:  Breast Cancer Res Treat       Date:  2017-07-12       Impact factor: 4.872

2.  Racial/ethnicity disparities in invasive breast cancer among younger and older women: An analysis using multiple measures of population health.

Authors:  Mei-Chuan Hung; Donatus U Ekwueme; Sun Hee Rim; Arica White
Journal:  Cancer Epidemiol       Date:  2016-10-25       Impact factor: 2.984

3.  The Economics of Breast Cancer in Younger Women in the U.S.: The Present and Future.

Authors:  Donatus U Ekwueme; Justin G Trogdon
Journal:  Am J Prev Med       Date:  2016-02       Impact factor: 5.043

4.  A Practical Guide to Conducting a Systematic Review and Meta-analysis of Health State Utility Values.

Authors:  Stavros Petrou; Joseph Kwon; Jason Madan
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

5.  Productivity costs associated with metastatic breast cancer in younger, midlife, and older women.

Authors:  Justin G Trogdon; Xuejun Liu; Katherine E Reeder-Hayes; Jason Rotter; Donatus U Ekwueme; Stephanie B Wheeler
Journal:  Cancer       Date:  2020-07-10       Impact factor: 6.921

6.  Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands.

Authors:  Renée Else Michels; Maria de Fransesco; Koshu Mahajan; Gerald J D Hengstman; Krijn M H Schiffers; Sangeeta Budhia; Gerard Harty; Marieke Krol
Journal:  Appl Health Econ Health Policy       Date:  2019-12       Impact factor: 2.561

7.  A Systematic Literature Review of Health Utility Values in Breast Cancer.

Authors:  Manraj N Kaur; Jiajun Yan; Anne F Klassen; Justin P David; Dilshan Pieris; Manraj Sharma; Louise Bordeleau; Feng Xie
Journal:  Med Decis Making       Date:  2022-01-18       Impact factor: 2.749

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.